Cancer Immunity
Overview
Cancer Immunity is a scientific journal, published since 2001 in English. The journal's country of origin is United States and its primary focus areas are oncology and allergy & immunology.
Details
Details
Abbr.
Cancer Immun
Start
2001
End
2013
e-ISSN
1424-9634
Country
United States
Language
English
Specialties
Oncology
Allergy & Immunology
Allergy & Immunology
Recent Articles
1.
Yokota S, Facciponte J, Kelleher Jr R, Shultz L, Loyall J, Parsons R, et al.
Cancer Immun
. 2013 Jul;
13:11.
PMID: 23885217
Despite an initial response to chemotherapy, most patients with ovarian cancer eventually progress and succumb to their disease. Understanding why effector T cells that are known to infiltrate the tumor...
2.
Chen Y, Cao D, Chiu R, Lee P
Cancer Immun
. 2013 Jul;
13:10.
PMID: 23885216
Cancer/Testis (CT) antigens are normally only expressed in germ cells and yet are aberrantly activated in a wide variety of human cancers. Most chromosome X-encoded CT antigens (CT-X) show restricted...
3.
Fox L, Miksanek J, May N, Scharf L, Lockridge J, Veerapen N, et al.
Cancer Immun
. 2013 Jul;
13:9.
PMID: 23885215
Invariant natural killer T (iNKT) cells are innate T lymphocytes that specifically recognize α-linked glycosphingolipids (α-GSLs) as antigens presented by CD1d molecules. Activating iNKT cells by administering α-GSLs improves disease...
4.
Hardwick N, Buchan S, Ingram W, Khan G, Vittes G, Rice J, et al.
Cancer Immun
. 2013 Jul;
13:16.
PMID: 23882161
We have previously identified the novel Cancer/Testis antigen PASD1 by immunoscreening a testis library with pooled acute myeloid leukemia (AML) patient sera. To develop a cytotoxic T lymphocyte (CTL)-inducing vaccine,...
5.
Vigneron N, Stroobant V, Van den Eynde B, van der Bruggen P
Cancer Immun
. 2013 Jul;
13:15.
PMID: 23882160
The plethora of tumor antigens that have been--and are still being--defined required systematization to provide a comprehensive overview of those tumor antigens that are the most relevant targets for cancer...
6.
Simpson-Abelson M, Loyall J, Lehman H, Barnas J, Minderman H, OLoughlin K, et al.
Cancer Immun
. 2013 Jul;
13:14.
PMID: 23882159
Human memory T cells present in ovarian tumor ascites fluids fail to respond normally to stimulation via the T cell receptor (TCR). This immunosuppression is manifested by decreases in NF-κB...
7.
Janetzki S, Hoos A, Melief C, Odunsi K, Romero P, Britten C
Cancer Immun
. 2013 Jul;
13:13.
PMID: 23882158
No abstract available.
8.
von Boehmer L, Mattle M, Bode P, Landshammer A, Schafer C, Nuber N, et al.
Cancer Immun
. 2013 Jul;
13:12.
PMID: 23882157
During cancer progression, malignant cells may evade immunosurveillance. However, evidence for immunological escape in humans is scarce. We report here the clinical course of a melanoma patient whose initial tumor...
9.
Spear P, Wu M, Sentman M, Sentman C
Cancer Immun
. 2013 Jul;
13:8.
PMID: 23833565
The Natural Killer Group 2D (NKG2D) receptor plays an important role in protecting the host from infections and cancer. By recognizing ligands induced on infected or tumor cells, NKG2D modulates...
10.
Weber J, Hamid O, Amin A, ODay S, Masson E, Goldberg S, et al.
Cancer Immun
. 2013 Jul;
13:7.
PMID: 23833564
We describe a randomized three-arm phase I study of ipilimumab administered alone (I group) or in combination with dacarbazine (D group) or carboplatin/paclitaxel (CP group) in patients with previously untreated...